All clinical trials are covered by a series of regulations that seek to protect the rights, safety and welfare of participating patients. The regulations covering PET studies are especially complex to interpret because of the specialized nature of the language of the regulations and of PET studies themselves. It is often unclear whether the application demands that the radiotracer used be treated as an investigational medical product. This paper is intended to act as a general guide for UK researchers planning to perform PET research in humans by clarifying key aspects of the regulations that may affect the study and/or the radiopharmaceutical manufacturing process, providing links to useful information sources, introducing the concept of a UK Medicines and Healthcare products Regulatory Agency (MHRA) PET expert panel and outlining the value of sharing investigational medical product dossiers.
Fleming, I. N., Whelan, M., Baxendale, R., Gilbert, F. J., Matthews, P. P., & Aigbirhio, F. I. (2012). Positron emission tomography radiopharmaceutical studies in humans: a guide to regulations for academic researchers. Nuclear Medicine Communications, 33(9), 899-906. https://doi.org/10.1097/MNM.0b013e328356737f